Yesterday after the market closed, the United States Army announced that it is consolidating 75 separate software agreements into a single, force-wide contract with Palantir. The new framework allows the Army and any other Department of Defense entity that chooses to opt in, to place orders worth up to USD 10 billion in Palantir products for data-integration, analytics and artificial-intelligence over the next ten years. The Army is not obliged to use the full amount, but the streamlined structure sharply reduces bureaucracy and fees, enabling faster deployment of new technologies to soldiers. This is the largest contract in Palantir’s history and one of the biggest software deals in Pentagon history.
Palantir will also report its fiscal-year 2025 second-quarter results on Monday, 4 August 2025, after the market close. The market consensus calls for revenue of about USD 939–940 million and adjusted earnings per share (EPS) of roughly USD 0.14, implying revenue growth of about 40 % y/y and profit growth of more than 50 %. Analysts will be watching closely to see whether the commercial rollout of the Artificial Intelligence Platform (AIP) and the new Army contract structure help maintain operating margins above 40 %.
Source: xStation 5
TSMC Earnings Preview: Will the Key Semiconductor Supplier Surprise the Market?
US Open: American Indices Rally on Anticipated End of Fed Balance Sheet Reduction
Bank of America, Wells Fargo, and Morgan Stanley: Q3 2025 Earnings Overview
Abbott reports no surprises in Q3, but tariff risks and lowered forecasts drag the share price down💡
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
